Jim Jersey, president and CEO at Agilux, said: “In launching the LC/MS/MS GLP bioanalytical services, we have challenged ourselves to be as innovative as we were in discovery, without compromising outstanding compliance and customer service.
“At Agilux, we have challenged ourselves to innovate to the advantage of our clients. Our highly successful Discovery 2.0 has demonstrated that there was room to innovate in the discovery bioanalytical services space. In launching the LC/MS/MS GLP bioanalytical services, we have challenged ourselves to be as innovative as we were in discovery, without compromising outstanding compliance and customer service”